Last update 21 Nov 2024

Ceforanide

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[O-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid, 7β-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid

+ [5]

Target

PBPs

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesCardiovascular DiseasesDigestive System Disorders+ [4]

Active Indication

Bone and joint infectionsEndocarditisInfections of musculoskeletal system+ [7]

Inactive Indication

Bacterial InfectionsSurgical Wound Infection

Originator Organization

Bristol Myers Squibb Co.

Active Organization

China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute

Jiangsu Sinoya Biomedical Technology Co., Ltd.

Inactive Organization

Bristol Laboratories Ltd.

Drug Highest PhasePhase 1

First Approval Date

US (24 May 1984),

Bacterial InfectionsSurgical Wound Infection

Regulation-

Structure

Molecular FormulaC20H21N7O6S2

InChIKeySLAYUXIURFNXPG-CRAIPNDOSA-N

CAS Registry60925-61-3

Clinical Trials associated with Ceforanide

CTR20181459 / Not yet recruitingPhase 1

注射用头孢雷特在健康受试者中的药代动力学研究

[Translation] Study on the pharmacokinetics of cefuroxime for injection in healthy subjects

拟在健康受试者中进行注射用头孢雷特单次和多次给药人体药动学研究。评价健康受试者单次和多次静脉输注注射用头孢雷特的耐受性及安全性，计算主要药动学参数，评价单次和多次静脉输注注射用头孢雷特后受试者体内的药动学特征；同时考察尿药排泄情况。

[Translation]

It is planned to conduct a single and multiple dose human pharmacokinetic study of Cefuroxime for Injection in healthy subjects. The tolerability and safety of single and multiple intravenous infusions of Cefuroxime for Injection in healthy subjects will be evaluated, the main pharmacokinetic parameters will be calculated, and the pharmacokinetic characteristics of Cefuroxime for Injection in subjects after single and multiple intravenous infusions will be evaluated; at the same time, the urinary excretion of the drug will be investigated.

Start Date-

Sponsor / Collaborator

China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute

[+1]

100 Clinical Results associated with Ceforanide

100 Translational Medicine associated with Ceforanide

100 Patents (Medical) associated with Ceforanide

117

Literatures (Medical) associated with Ceforanide

15 May 2021·AgingQ3 · MEDICINE

Identification of key pathways and genes in carotid atherosclerosis through bioinformatics analysis of RNA-seq data

Q3 · MEDICINE

Article

Author: Jiang, Qunlong ; Wang, Peijian ; Li, Zhongchen ; Xing, Xiaohui ; Zhang, Yinjiang ; Zhang, Liyong ; Chen, Kun ; Xiao, Yilei ; Hao, Jiheng ; Wang, Jiyue

While acknowledging carotid atherosclerosis (CAS) as a risk factor for ischemic stroke, reports on its pathogenesis are scarce. This study aimed to explore the potential mechanism of CAS through RNA-seq data analysis. Carotid intima tissue samples from CAS patients and healthy subjects were subjected to RNA-seq analysis, which yielded, 1,427 differentially expressed genes (DEGs) related to CAS. Further, enrichment analysis (Gene Ontology, KEGG pathway, and MOCDE analysis) was performed on the DEGs. Hub genes identified via the protein-protein interaction network (PPI) were then analyzed using TRRUST, DisGeNET, PaGenBase, and CMAP databases. Results implicated inflammation and immunity in the pathogenesis of CAS. Also, lung disease was associated with CAS. Hub genes were expressed in multiple diseases, mainly regulated by RELA and NFKB1. Moreover, three small-molecule compounds were found via the CMAP database for management of CAS; hub genes served as potential targets. Collectively, inflammation and immunity are the potential pathological mechanisms of CAS. This study implicates CeForanide, Chenodeoxycholic acid, and 0317956-0000 as potential drug candidates for CAS treatment.

15 Jun 2019·Bioinformation

Virtual screening of inhibitors against Envelope glycoprotein of Chikungunya Virus: a drug repositioning approach

Article

Author: Gupta, Amita ; Agarwal, Garima ; Gupta, Sanjay ; Gupta, Vandana ; Chaudhary, Vijay Kumar ; Gabrani, Reema

Chikungunya virus (CHIKV) a re-emerging mosquito-borne alpha virus causes significant distress which is further accentuated in the lack of specific therapeutics or a preventive vaccine, mandating accelerated research for anti-CHIKV therapeutics. In recent years, drug repositioning has gained recognition for the curative interventions for its cost and time efficacy. CHIKV envelope proteins are considered to be the promising targets for drug discovery because of their essential role in viral attachment and entry in the host cells. In the current study, we propose structure-based virtual screening of drug molecule on the crystal structure of mature Chikungunya envelope protein (PDB 3N41) using a library of FDA approved drug molecules. Several cephalosporin drugs docked successfully within two binding sites prepared at E1-E2 interface of CHIKV envelop protein complex with significantly low binding energies. Cefmenoxime, ceforanide, cefotetan, cefonicid sodium and cefpiramide were identified as top leads with a cumulative score of -67.67, -64.90, -63.78, -61.99, and - 61.77, forming electrostatic, hydrogen and hydrophobic bonds within both the binding sites. These shortlisted leads could be potential inhibitors of E1-E2 hetero dimer in CHIKV, hence might disrupt the integrity of envelope glycoprotein leading to loss of its ability to form mature viral particles and gain entry into the host.

01 Aug 2008·Pediatrics in Review

Cephalosporins: A Review

Article

Author: Bratcher, Denise ; Harrison, Christopher J

1. Christopher J. Harrison, MD* 2. Denise Bratcher, DO* 1. *Children's Mercy Hospitals and Clinics, Pediatric Infectious Diseases, University of Missouri at Kansas City, Kansas City, Mo After completing this article, readers should be able to: 1. Describe the mechanism of action of cephalosporins. 2. Delineate the two most common mechanisms of resistance to penicillins. 3. Discuss the most common adverse effects of common cephalosporins. 4. List which cephalosporins have activity against Pseudomonas. Cephalosporins are beta-lactam antimicrobials that share mechanisms of action and a similar structure with penicillins (Figure⇓). Penicillins and cephalosporins have the same four-member “core” beta-lactam ring, but cephalosporins have an additional atom in the side ring. Modified side chains on either ring alter antimicrobial activity, resistance to beta-lactamases, or pharmacokinetics. Penicillin-susceptible pathogens usually are cephalosporin-susceptible. Exceptions are Listeria and Pasteurella sp. Cephalosporins have activity against common gram-negative organisms such as Escherichia coli , nontypeable Haemophilus influenzae (ntHi), and methicillin-susceptible Staphylococcus aureus (MSSA), but all methicillin-resistant S aureus (MRSA) and enterococci are cephalosporin-resistant. Because of minimal use or current unavailability, we will not discuss cephalothin, moxalactam, cefamandole, cefonicid, ceforanide, ceftizoxime, cefoperazone, cefpirome, cefmetazole, or cefotetan. Figure. Cephalosporin versus penicillin ring structures. The solid arrows indicate the core four-member beta-lactam ring within both penicillins and cephalosporins. Open arrows indicate the five- and six-member side rings for penicillins and cephalosporins, respectively. R indicates additional side chain sites where substitutions of various chemical groups produce different antimicrobial spectra, pharmacokinetics, or stability to beta-lactamases. To help understand the mechanism of action of cephalosporins, rigid bacterial cell walls can be considered as a series of repeating interlocking units reminiscent of floor tiles. During replication, a bacterium removes “tiles” circumferentially to allow cell division via a pinching-like action, while quickly placing new “tiles” at the ends of what have become two bacteria. This process requires enzymes to interlock replacement tiles. Such enzymes are the targets of beta-lactam antibiotics and are called penicillin-binding proteins (PBPs). Antibiotic action requires binding to PBPs, preventing them from closing the …

100 Deals associated with Ceforanide

External Link

KEGG	Wiki	ATC	Drug Bank
D00259	Ceforanide	J01DC11	DB00923

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infections of musculoskeletal system	Phase 1	CN	China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute	27 Aug 2018
Infections of musculoskeletal system	Phase 1	CN	Jiangsu Sinoya Biomedical Technology Co., Ltd.	27 Aug 2018
Sepsis	Phase 1	CN	Jiangsu Sinoya Biomedical Technology Co., Ltd.	27 Aug 2018
Sepsis	Phase 1	CN	China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute	27 Aug 2018
Skin Diseases, Infectious	Phase 1	CN	Jiangsu Sinoya Biomedical Technology Co., Ltd.	27 Aug 2018
Skin Diseases, Infectious	Phase 1	CN	China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute	27 Aug 2018
Urethral Infection	Phase 1	CN	China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute	27 Aug 2018
Urethral Infection	Phase 1	CN	Jiangsu Sinoya Biomedical Technology Co., Ltd.	27 Aug 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis